Ergomed has signed its first regional licensing agreement for its Haemostatix products (PeproStat™ and ReadyFlow™) with Boryung Pharmaceutical in South Korea. Ergomed is eligible to an undisclosed upfront payment, development milestone payments and a double-digit share of product sales. PeproStat™ is on track to produce Phase IIb data in late October and, subject to positive data, could potentially reach the market in South Korea in 2021. We believe positive Phase IIb data will be a catalyst for ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Ergomed - First commercial Haemostatix deal
- Published:
27 Sep 2017 -
Author:
Sheena Berry -
Pages:
3
Ergomed has signed its first regional licensing agreement for its Haemostatix products (PeproStat™ and ReadyFlow™) with Boryung Pharmaceutical in South Korea. Ergomed is eligible to an undisclosed upfront payment, development milestone payments and a double-digit share of product sales. PeproStat™ is on track to produce Phase IIb data in late October and, subject to positive data, could potentially reach the market in South Korea in 2021. We believe positive Phase IIb data will be a catalyst for ....